Rockefeller Capital Management L.P. grew its position in shares of Danaher Co. (NYSE:DHR – Free Report) by 2.6% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 430,588 shares of the conglomerate’s stock after acquiring an additional 10,756 shares during the period. Rockefeller Capital Management L.P.’s holdings in Danaher were worth $119,694,000 as of its most recent SEC filing.
A number of other institutional investors also recently modified their holdings of DHR. FMR LLC increased its position in Danaher by 15.8% during the 3rd quarter. FMR LLC now owns 23,617,424 shares of the conglomerate’s stock valued at $6,566,116,000 after purchasing an additional 3,217,631 shares during the period. TD Asset Management Inc lifted its holdings in Danaher by 99.0% in the second quarter. TD Asset Management Inc now owns 1,358,706 shares of the conglomerate’s stock worth $339,473,000 after buying an additional 675,952 shares during the period. Massachusetts Financial Services Co. MA boosted its position in Danaher by 22.7% during the 2nd quarter. Massachusetts Financial Services Co. MA now owns 3,047,728 shares of the conglomerate’s stock valued at $761,475,000 after acquiring an additional 563,546 shares in the last quarter. International Assets Investment Management LLC grew its holdings in shares of Danaher by 40,196.5% during the 3rd quarter. International Assets Investment Management LLC now owns 429,964 shares of the conglomerate’s stock worth $119,539,000 after acquiring an additional 428,897 shares during the period. Finally, Montrusco Bolton Investments Inc. lifted its stake in shares of Danaher by 30.4% in the 3rd quarter. Montrusco Bolton Investments Inc. now owns 1,705,884 shares of the conglomerate’s stock valued at $465,617,000 after purchasing an additional 397,671 shares during the period. 79.05% of the stock is currently owned by hedge funds and other institutional investors.
Danaher Trading Up 1.0 %
Shares of DHR stock opened at $238.83 on Friday. The company has a current ratio of 1.37, a quick ratio of 1.01 and a debt-to-equity ratio of 0.32. Danaher Co. has a 12-month low of $215.68 and a 12-month high of $281.70. The stock has a market capitalization of $172.50 billion, a P/E ratio of 45.58, a P/E/G ratio of 4.39 and a beta of 0.85. The firm’s 50 day moving average is $255.25 and its 200 day moving average is $259.52.
Danaher Announces Dividend
The firm also recently disclosed a quarterly dividend, which was paid on Friday, October 25th. Stockholders of record on Friday, September 27th were paid a $0.27 dividend. This represents a $1.08 annualized dividend and a dividend yield of 0.45%. The ex-dividend date was Friday, September 27th. Danaher’s dividend payout ratio (DPR) is presently 20.61%.
Analyst Ratings Changes
Several equities research analysts recently weighed in on DHR shares. KeyCorp upped their price target on Danaher from $290.00 to $310.00 and gave the stock an “overweight” rating in a research note on Wednesday, October 23rd. Evercore ISI increased their price target on shares of Danaher from $275.00 to $278.00 and gave the stock an “outperform” rating in a research note on Tuesday, October 1st. TD Cowen boosted their price objective on shares of Danaher from $310.00 to $315.00 and gave the stock a “buy” rating in a research note on Wednesday, October 23rd. StockNews.com raised shares of Danaher from a “hold” rating to a “buy” rating in a research note on Wednesday. Finally, Wolfe Research upgraded Danaher from a “peer perform” rating to an “outperform” rating and set a $285.00 price target on the stock in a research note on Thursday, October 31st. Five equities research analysts have rated the stock with a hold rating and fifteen have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $287.16.
View Our Latest Report on Danaher
About Danaher
Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.
See Also
- Five stocks we like better than Danaher
- Ride Out The Recession With These Dividend KingsĀ
- Zeta Global Holdings Insiders Buy Stock After Short-Report
- What is Put Option Volume?
- 3 Stocks That Never Lived Up to the Hype
- Natural Gas Prices Continue To Rally, These Stocks Should Benefit
- 3 Stocks to Ride the Manufacturing Sector’s Big Comeback
Want to see what other hedge funds are holding DHR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Danaher Co. (NYSE:DHR – Free Report).
Receive News & Ratings for Danaher Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Danaher and related companies with MarketBeat.com's FREE daily email newsletter.